Oral vancomycin plus SBRT in early NSCLC, USA
44 gut microbiome samples from USA patients with early-stage non-small cell lung cancer, from a randomized, open-label pilot trial comparing oral vancomycin plus stereotactic body radiotherapy versus SBRT alone. machine-written summary
44 samples · 44 runs · US · Age unknown · 2024 · 2.17 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 456 sample values (antibiotic exposure, collection date, country, health condition, intervention, intervention detail, latitude, location region) |
| ✓ Abstract / description | 72 sample values (health condition, health condition detail) |
| ○ Full text | read; no usable statement or table · PMC12258320 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
longitudinal — not resolved
13 of 16 people sampled more than once (41 samples; median 3, up to 5 per person). Schedule stated by the source: “stool during SBRT and at 1, 3, 6 and 12 months post-SBRT” (time origin: intervention_start); stated follow-up 12 mo.
Genera, mean relative abundance over 36 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 44 | 100% | 44 | |||
| health_condition | 44 | 100% | 16 | 28 | ||
| subject_id | 44 | 100% | 44 | |||
| antibiotic_exposure | 44 | 100% | 44 | |||
| collection_date | 44 | 100% | 44 | |||
| detailed_location | 44 | 100% | ||||
| health_condition_detail | 44 | 100% | 44 | |||
| intervention | 44 | 100% | 44 | |||
| intervention_detail | 44 | 100% | 44 | |||
| latitude | 44 | 100% | 44 | |||
| location_region | 44 | 100% | 44 | |||
| longitude | 44 | 100% | 44 | |||
| timepoint_label | 44 | 100% | 44 |
- Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. 2025 PMID 40639850 PMC12258320 own_data
Archive description
We report the results of a randomized, open-label pilot study evaluating oral vancomycin combined with SBRT in early-stage non-small cell lung cancer. Building on prior research, vancomycin was found to enhance antitumor effects by modulating gut microbiota and boosting immune responses notably improving progression-free and overall survival (P.F.S. and O.S.). Patients treated with vancomycin (125 mg QID for 5 weeks starting one week before SBRT) showed increased dendritic cell and T-cell activation, and significant changes in gut microbiome composition and metabolite profiles, including reduced Short Chain Fatty Acids and elevated TNF-beta levels. With minimal adverse events, vancomycin appears to synergistically enhance RT-induced antitumor immunity, suggesting a viable strategy for improving oncological outcomes. Further studies with larger cohorts are needed to confirm these results.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.85. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site run.scientific_name · “human gut metagenome”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN43405255 | antibiotic_exposure | no | R1 | 0.90 | biosample_attr | No abx |
| SAMN43405255 | collection_date | 2020 | R1 | 0.90 | biosample.attribute:collection_date | 2020 |
| SAMN43405255 | country | US | R1 | 0.90 | sample.attr.geo_loc_name | USA |
| SAMN43405256 | health_condition | other_cancer | R1 | 0.60 | biosample_attr | End SBRT |
| SAMN43405255 | health_condition | other_cancer | R4 | 0.50 | paper.abstract | early-stage non-small cell lung cancer (NSCLC) |
| SAMN43405255 | health_condition_detail | early-stage non-small cell lung cancer (NSCLC), medically inoperable | R4 | 0.50 | study.title | medically inoperable Early-Stage Non-small Cell Lung Cancer |
| SAMN43405255 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:study_group | study_group: Baseline |
| SAMN43405256 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:treatment | treatment: control |
| SAMN43405255 | intervention_detail | baseline before vancomycin/SBRT | R1 | 0.90 | biosample.attribute:study_group | study_group: Baseline |
| SAMN43405256 | intervention_detail | control arm, no vancomycin | R1 | 0.90 | biosample.attribute:treatment | treatment: control |
| SAMN43405255 | latitude | 39.9560 | R1 | 0.90 | biosample.attribute:lat_lon | 39.956 N 75.193 W |
| SAMN43405255 | location_region | Pennsylvania | R1 | 0.60 | biosample.attribute:lat_lon | 39.956 N 75.193 W |
| SAMN43405255 | longitude | -75.1930 | R1 | 0.90 | biosample.attribute:lat_lon | 39.956 N 75.193 W |
| SAMN43405255 | subject_id | BW05 | R1 | 0.85 | sample.attr.host_subject_id | BW05 |
| SAMN43405255 | timepoint_label | Baseline | R1 | 0.85 | biosample.attribute:study_group | Baseline |
Sequencing
44 runs over 44 samples · mean 3.01 Gbp per run (median 2.17 Gbp, total 132.37 Gbp; 44 runs with a base count) · layout PAIRED 44 · platform ILLUMINA 44 · models Illumina NovaSeq 6000 (44) · 82% of runs with a Sandpiper profile · first public 2024-08-31
Authors (25)
Feigenberg SJ first · Costabile F · Tanes C · Bittinger K · O'Connor R · Agarwal D · Skoufos G · Salaris S · Hatzigeorgiou A · Kostopoulos N · Lloyd S · Friedes C · Chen L · Yegya-Raman N · Cengel K · Levin W · Valentić B · Quarton T · Shestov AA · Berman A · Bradley J · Maity A · Koumenis C · Ben-Josef E · Facciabene A last
Downloads
PRJNA1153928.csv.gz (2.4 KB) · parquet (72.6 KB) — all 44 samples, every field with route and confidence · PRJNA1153928_determinations.csv.gz (4.5 KB) — 528 evidence rows